LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Pictilisib | 1.11 | uM | LJP6 | 3 | D21 | 72 | hr | 1476 | 1982 | 3694 | 0.5365 | 0.2279 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 1 | N09 | 72 | hr | 1476 | 1978 | 3694 | 0.5355 | 0.2261 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 2 | N09 | 72 | hr | 1476 | 2420 | 3694 | 0.6551 | 0.4254 |
| SK-BR-3 | Gefitinib | 1.11 | uM | LJP6 | 3 | N09 | 72 | hr | 1476 | 2261 | 3694 | 0.6121 | 0.3537 |
| SK-BR-3 | Geldanamycin | 1.11 | uM | LJP5 | 1 | O03 | 72 | hr | 1476 | 1697 | 3694 | 0.4594 | 0.0993 |
| SK-BR-3 | Geldanamycin | 1.11 | uM | LJP5 | 2 | O03 | 72 | hr | 1476 | 1518 | 3694 | 0.4109 | 0.0186 |
| SK-BR-3 | Geldanamycin | 1.11 | uM | LJP5 | 3 | O03 | 72 | hr | 1476 | 1421 | 3694 | 0.3847 | -0.0251 |
| SK-BR-3 | Geldanamycin | 1.11 | uM | LJP6 | 1 | O03 | 72 | hr | 1476 | 1367 | 3694 | 0.3701 | -0.0495 |
| SK-BR-3 | Geldanamycin | 1.11 | uM | LJP6 | 2 | O03 | 72 | hr | 1476 | 1510 | 3694 | 0.4088 | 0.0150 |
| SK-BR-3 | Geldanamycin | 1.11 | uM | LJP6 | 3 | O03 | 72 | hr | 1476 | 1526 | 3694 | 0.4131 | 0.0222 |
| SK-BR-3 | GSK1059615 | 1.11 | uM | LJP5 | 1 | E03 | 72 | hr | 1476 | 1656 | 3694 | 0.4483 | 0.0809 |
| SK-BR-3 | GSK1059615 | 1.11 | uM | LJP5 | 2 | E03 | 72 | hr | 1476 | 1426 | 3694 | 0.3860 | -0.0229 |
| SK-BR-3 | GSK1059615 | 1.11 | uM | LJP5 | 3 | E03 | 72 | hr | 1476 | 1523 | 3694 | 0.4123 | 0.0209 |
| SK-BR-3 | GSK1059615 | 1.11 | uM | LJP6 | 1 | C03 | 72 | hr | 1476 | 1460 | 3694 | 0.3952 | -0.0075 |
| SK-BR-3 | GSK1059615 | 1.11 | uM | LJP6 | 2 | C03 | 72 | hr | 1476 | 1492 | 3694 | 0.4039 | 0.0069 |
| SK-BR-3 | GSK1059615 | 1.11 | uM | LJP6 | 3 | C03 | 72 | hr | 1476 | 1518 | 3694 | 0.4109 | 0.0186 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 1 | H21 | 72 | hr | 1476 | 3366 | 3694 | 0.9112 | 0.8521 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 2 | H21 | 72 | hr | 1476 | 3648 | 3694 | 0.9875 | 0.9792 |
| SK-BR-3 | GSK1904529A | 1.11 | uM | LJP6 | 3 | H21 | 72 | hr | 1476 | 3405 | 3694 | 0.9218 | 0.8696 |
| SK-BR-3 | Omipalisib | 1.11 | uM | LJP6 | 1 | N03 | 72 | hr | 1476 | 1057 | 3694 | 0.2861 | -0.1893 |
| SK-BR-3 | Omipalisib | 1.11 | uM | LJP6 | 2 | N03 | 72 | hr | 1476 | 1394 | 3694 | 0.3774 | -0.0373 |
| SK-BR-3 | Omipalisib | 1.11 | uM | LJP6 | 3 | N03 | 72 | hr | 1476 | 1380 | 3694 | 0.3736 | -0.0436 |
| SK-BR-3 | GSK 690693 | 1.11 | uM | LJP5 | 1 | F21 | 72 | hr | 1476 | 2829 | 3694 | 0.7658 | 0.6099 |
| SK-BR-3 | GSK 690693 | 1.11 | uM | LJP5 | 2 | F21 | 72 | hr | 1476 | 2715 | 3694 | 0.7350 | 0.5585 |
| SK-BR-3 | GSK 690693 | 1.11 | uM | LJP5 | 3 | F21 | 72 | hr | 1476 | 2835 | 3694 | 0.7675 | 0.6126 |